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Summary
The effect of nifedipine 5 mg administered sublingually to
pregnant hypertensive patients was examined in a randomlsed
controlled double-blind study. The effect on maternal blood
pressure and the fetal umbilical artery Doppler waveform was
studied for 30 minutes before and 30 minutes after administra-
tion of the drug or placebo. This dose resulted in a significant
drop in maternal blood pressure 30 minutes after administra-
tion and did not result in a significant change in the Doppler
umbilical artery waveform (in fetuses with normal waveforms)
when compared with a control group.
S Atr Med J 1991; 79: 192-194.
Nifedipine is a pyridine derivative and is one of the most
potent of the calcium entry blockers. Despite having been
used extensively in obstetrics, both for the treatment of severe
pregnancy-associated hypertension1 and to suppress preterm
labour,2 the fetal effects of the drug have not been fully
elucidated. The effect on the fetal circulation must be studied
before nifedipine can become accepted for use in pregnant
patients.
Doppler ultrasound velocity waveforms recorded from the
umbilical artery can be used to assess fetal well-being3 and
give information on the fetal circulation. Pulsed Doppler
ultrasound evaluation is an indirect way of measuring blood
volume flow and velocity; it has an accepted daily variability4
and is a relatively simple method of clinical investigation.
This clinical experiment was designed to see if administration
of nifedipine or a placebo changed the umbilical artery wave-
form characteristics, thus giving information on any possible
fetal effects.
then randomly allocated to receive nifedipine 5 mg or a
placebo by virture of the last digit of their folder number.
The nifedipine was administered sublingually as a single 5
mg dose, the placebo capsule was a similar size and contained
vitamin syrup. The ultrasonographer and patient were unaware
which capsule had been given.
Patients were examined supine on the ultrasound couch
with 30° lateral tilt. Ten minutes were allowed before starting
the study to reassure the patient. Blood pressure recordings
were taken at 5-minute intervals from 0 to 60 minutes using
the Critikon Dinamp Vital Signs Monitor (18465X). Fetal umbilical
artery waveform parierns were measured using the Aloka
Doppler Unit (UGR-34) with a lOO Hz fJ.lter at IO-minute
intervals from 0 to 60 minutes. The umbilical artery was identi-
fied with a B-mode scanner and the sample volume placed
over the vessel; each Doppler trace had an umbilical vein
tracing throughout. The Doppler trace was observed until a
constant signal was obtained and the A and B values were
measured from one representative waveform. The ·waveform
was one of five waveforms that were uniform and a photograph
was taken to check that it was representative. Adjacent waves
were sampled to ensure uniformity. The Pourcelot ratios was
calculated from the A and B values (Fig. 1) using standard
calipers; it was not corrected for fetal heart rate, since the rate
was in the normal range (120 - 16O/min) in every patient
except case 3 in the nifedipine group and there was no shift>
20/min in any patient. Normalisation of the ratio for heart rate
was unnecessary under these circumstances.6
Max
Subjects and methods
Nineteen hypertensive pregnant women who were> 28 weeks
pregnant were studied. All patients gave wrinen, informed
consent to the study, which was approved by the University of
Cape Town Ethics Comminee. The inclusion criteria required
that singleton pregnancies with reactive non-stress tests were
studied. Hypertension was defmed as a mean diastolic blood
pressure, taken over four 6-hourly readings with a standard
mercury sphygmomanometer, ~ 90 mmHg. The patients were
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Fig. 1. Pourcelot ratio: A - B . Definition of Pourcelot ratio from
A
one umbilical artery waveform.
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Fig. 2. Mean diastolic blood pressure (mmHg) plotted against









Placebo group U-tests between










TABLE I. NIFEDIPINE GROUP COMPARED WITH PLACEBO
GROUP FOR GESTATIONAL AGE, WEIGHT ANn HEIGHT
(MEAN ± SO)
The characteristics of the two groups of patients are shown in
Tables I and 11. The Mann-Whitney non-parametric V-test
showed no significant difference between the two groups (P>
0,05) with respect to gestational age, height and weight.
Maternal diastolic blood pressure
Maternal diastolic blood pressure is shown in Fig. 2.
Repeated measures analysis was carried out on diastolic blood
pressure using the repeated measurements taken at 5-minute
intervals from 35 to 60 minutes. A significant treatment X
time interaction was found (P < 0,001). This implies that the
proflles of mean diastolic blood pressures over time do not lie
parallel to one another. Differences at each point can therefore
be tested. Univariate tests were carried out at each point and a
significant fall in diastolic blood pressure was noted at 60
minutes (30 minutes after administration of the drug).
Maternal pulse rate
Maternal pulse rate is shown in Fig. 3. Repeated measure-
ment analysis of variants showed a significant difference (P <
0,00I) for treatment by time interaction.
Fetal heart rate
Fetal heart rate, as recorded with a eardiotocograph before
and after administration of nifedipine or placebo, is shown in
Table 11. The Mann-Whitney non-parametric V-test showed
no significant change in the fetal heart rate.
TABLE 11. INDIVIDUAL MATERNAL AND FETAL MEASUREMENTS BEFORE AND AFTER ADMINISTRATION NIFEDIPINE 5 mg
OR PLACEBO
Mean diastolic blood Mean maternal pulse rate Mean fetal heart rate
pressure (mmHg) (/min) (/min)
Gestational
Mean Pourcelot ratio
Patient Before After Before After Before After age (wks) Before After
1 85 81 88 105 128 137 40 0,56 0,61
2 !TT 85 68 85 145 145 34 0,68 0,67
3 91 86 69 81 168 168 34 0,62 0,62
4 85 78 101 124 150 155 36 0,57 0,610
,g 5 93 75 76 100 140 145 36 0,58 0,5611
u 6 109 101 100 110 140 155 33 0,60 0,44ca
ii: 7 95 79 81 100 130 128 30 0,70 0,73
8 98 81 63 66 128 148 37 0,61 0,57
9 93 ff7 72 82 125 125 37 0,64 0,58
10 88 84 79 83 160 155 34 0,55 0,62
1 83 82 60 55 150 150 31 0,73 0,71
2 92 90 110 110 145 145 38 0,52 0,47
11 3 105 105 79 78 145 140 36 0,59 0,59c
76 74 160 160 32 0,58 0,60a. 4 105 107
;:; 5 93 90 100 100 135 140 38 0,55 0,61.!
6 ff7 91 60 59 125 125 31 0,70 0,69Z
7 83 79 83 84 145 145 41 0,66 0,65
8 83 78 80 79 145 155 33 0,64 0,64
9 84 78 96 99 135 135 36 0,66 0,62




































Fig. 4. Pourcelot ratio Y. time (a = placebo; e = nifedipine).
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Fig. 3. Mean maternal pulse rate plotted against time (min) for
placebo (a) and nifedipine (e).
Doppler waveform dataIPourcelot ratio
There were 5 missing values in this set of data due to fetal
breathing movements. A missing value was replaced by either
an interpolated value or the mean of the adjacent values. Fig. 4
gives the Pourcelot ratio v. time. Of note is that in both groups
all the Pourcelot ratios were normal at the time of testing. No
significant difference between the mean Pourcelot index in the
two groups was ~detected (P > 0,05). In the nifedipine group
the Pourcelot ratio measured at each time interval before and
after administration of the drug showed no statistical change.
Side-effects
There were no maternal side-effeets in either group. The
continuous cardiotocograph recordings did not show any
evidence of fetal distress.
Discussion
Nifedipine is a well-tolerated antihypertensive agent that is
useful for both emergency and maintenance treatment. It is
widely used in non-pregnant patients and is being prescribed
in the treatment of hypertension of pregnancy with increasing
frequency.
The use of any drug in the pregnant patient raises questions
about its action on placental perfusion. The placenta is perfused
by the fetal and maternal circulations independently and
maternal ingestion of a drug may change either component.
Study of the effects on the maternal blood supply of the
placenta has indicated that there is no change in this aspect of
placental perfusion.7 Animal models have shown that nifedipine
enters the fetal circulation in significant levels and increases
cerebral blood flow altering fetal haemodynamics.s Further
evidence for a possible effect of nifedipine on the fetal circula-
tion has been studied in vitro and showed an interference in
the contractile process in chorionic plate arteries and in the
umbilical artery9 leading to dilatation of these ve"ssels. Guiseppe
et al. lo have studied the effect of nifedipine on the fetal
umbilical artery waveform in normotensive patients and have
indicated that there may be a beneficial response. As a result
of the encouraging results in these trials we investigated the
fetal responses to nifedipine in hypertensive pregnancies.
Our results indicate that nifedipine 5 mg, when given
sublingually, does not cause any detrimental changes in the
Doppler waveform analysis expressed as the Pourcelot ratio.
This dose effected a drop in maternal diastolic blood pressure
which was significant at 60 minutes (30 minutes after admini-'
stration). It can be concluded that nifedipine 5 mg should
have no adverse effects on the fetal circulation in the first 30
minutes after administration in fetuses with normal initial
Doppler waveforms. There is a possibility that nifedipine in
larger doses may produce a beneficial effect· on the fetal
placental blood flow, and we are at present investigating this.
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